Abstract
Background
Trifunctional antibodies, such as catumaxomab (anti-EpCAM×anti-CD3) and ertumaxomab (anti-HER-2/neu×anti-CD3), transiently link immune effector cells to tumour cells, which results in cellular cytotoxicity towards the tumour cells. A functional immune system is therefore essential for effective anti-tumour activity. However, the commonly observed haematotoxicity of chemotherapeutics and radiation therapy may be associated with some degree of immunosuppression. Combining chemotherapy and trifunctional antibodies in cancer treatment requires understanding of the impact of chemotherapeutics on immune cell function and, thus, on the activity of trifunctional antibodies.
Methods
The effect of chemotherapeutic treatment on trifunctional antibody-mediated anti-tumour activity was assessed in vitro. Blood samples were collected from 12 head and neck squamous cell carcinoma patients after chemotherapy (5-fluorouracil, cisplatin) and radiotherapy, and from one healthy control donor. The immune cell status was analysed and mononuclear cells (MNC) were isolated. The potency of catumaxomab and ertumaxomab was assessed in a cytotoxicity assay using MNC isolated from each patient sample in co-culture with a tumour target cell line. The release of inflammatory cytokines was also monitored in the cell culture supernatant.
Results
Most patients included in this study had decreased immune cell counts during the course of chemotherapy. Nonetheless, an effective and concentration-dependent anti-tumour activity mediated by trifunctional antibodies was demonstrated using these patient immune effector cells. The immune response activity of the patient immune cells was not impaired one week after cisplatin administration or even three days after the last 5-fluorouracil treatment.
Conclusion
This study shows for the first time that immune effector cells from cancer patients undergoing standard chemotherapy and radiotherapy can be activated by trifunctional antibodies for efficient killing of tumour cells.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Köninki K, Barok M, Tanner M et al (2010) Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. Cancer Lett 294:211–219
Ciavarella S, Milano A, Dammacco F, Silvestris F (2010) Targeted therapies in cancer. BioDrugs 24:77–88
Gall JM, Davol PA, Grabert RC et al (2005) T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro. Exp Hematol 33:452–459
Watanabe M, Wallace PK, Keler T et al (1999) Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210. Breast Cancer Res Treat 53:199–207
Wimberger P, Xiang W, Mayr D et al (2003) Efficient tumour cell lysis by autologous, tumourresident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody. Int J Cancer 105:241–248
Chan JK, Hamilton CA, Cheung MK et al (2006) Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res 12:1859–1867
Reusch U, Sundaram M, Davol PA et al (2006) Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin Cancer Res 12:183–190
Seimetz D, Lindhofer H, Bokemeyer C (2010) Development and approval of the trifunctional antibody catumaxomab (anti-EpCAMxanti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 36:458–467
Heiss MM, Murawa P, Koralewski P et al (2010) The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 127:2209–2221
Zeidler R, Reisbach G, Wollenberg B et al (1999) Simultaneous activation of T-cells and accessory cells by a new class of intact bi-specific antibody results in efficient tumor cell killing. J Immunol 163:1246–1252
Zeidler R, Mysliwietz J, Csanady M et al (2000) The Fc-region of a new class of intact bi-specific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumor cells. Br J Cancer 83:261–266
Zeidler R, Mayer A, Gires O et al (2001) TNFalpha contributes to the anti-tumor activity of a bispecific, trifunctional antibody. Anticancer Res 21:3499–3503
Ruf P, Gires O, Jäger M et al (2007) Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Br J Cancer 97:315–321
Alanko S, Pelliniemi TT, Salmi TT (1992) Recovery of blood B-lymphocytes and serum immunoglobulins after chemotherapy for childhood acute lymphoblastic leukemia. Cancer 69:1481–1486
Campbell MJ, Scott J, Maecker HT (2005) Immune dysfunction and micrometastases in women with breast cancer. Breast Cancer Res Treat 91:163–171
Zignol M, Peracchi M, Tridello G et al (2004) Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. Cancer 101:635–641
Robert F, Childs HA, Spencer SA et al (1999) Phase I/IIa study of concurrent paclitaxel and cisplatin with radiation therapy in locally advanced non-small cell lung cancer: analysis of early and late pulmonary morbidity. Semin Radiat Oncol 9:136–147
Alanko S, Salmi TT, Pelliniemi TT (1994) Recovery of blood T-cell subsets after chemotherapy for childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 11:281–292
Arrieta O, Michel Ortega RM, Villanueva-Rodríguez G et al (2010) Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxelcisplatin chemotherapy: a prospective study. BMC Cancer 10:50
Standish LJ, Torkelson C, Hamill FA et al (2008) Immune defects in breast cancer patients after radiotherapy. J Soc Integr Oncol 6:110–121
Peters GJ, van Triest B, Backus HH et al (2000) Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed. Eur J Cancer 36:916–924
Shah MA, Schwartz GK (2001) Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 7:2168–2181
Jamieson ER, Lippard SJ (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99:2467–2498
Saridaki Z, Georgoulias V, Souglakos J (2010) Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. World J Gastroenterol 16:1177–1187
Han HS, Kim JS, Park JH et al (2009) Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy. J Korean Med Sci 24:910–917
Markasz L, Skribek H, Uhlin M et al (2008) Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes. J Immunother 31:283–293
Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8:59–73
Zitvogel L, Apetoh L, Ghiringhelli F et al (2008) The anticancer immune response: indispensable for therapeutic success? J Clin Invest 118:1991–2001. Review
Wu X, Feng QM, Wang Y et al (2010) The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy. Cancer Immunol Immunother 59:279–291
Friedman EJ (2002) Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 8:1765–1780
Chiriva-Internati M, Grizzi F, Pinkston J et al (2006) Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors. In Vitro Cell Dev Biol Anim 42:89–95
Hareyama M, Imai K, Ban T et al (1988) Effect of radiation on the expression of carcinoembryonic antigen on the membranes of human gastric adenocarcinoma cells — immunological study using monoclonal antibodies. Nippon Igaku Hoshasen Gakkai Zasshi 48:1572–1574
Gaugler MH, Squiban C, van der Meeren A et al (1997) Late and persistent up-regulation of intercellular adhesion molecule-1 (ICAM-1) expression by ionizing radiation in human endothelial cells in vitro. Int J Radiat Biol 72:201–209
Garnett CT, Palena C, Chakraborty M et al (2004) Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 64:7985–7994
Kiewe P, Hasmüller S, Kahlert S et al (2006) Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 12:3085–3091
Bokemeyer C, Heiss M, Gamperl H et al (2009) Safety of catumaxomab: cytokine-release-related symptoms as a possible predictive factor for efficacy in a pivotal phase II/III trial in malignant ascites. J Clin Oncol 27[Suppl]:Abstract 3036
Saito T, Berens ME, Welander CE (1986) Direct and indirect effects of human recombinant gamma-interferon on tumor cells in a clonogenic assay. Cancer Res 46:1142–1147
Gronau SS, Schmitt M, Thess B et al (2005) Trifunctional bispecific antibody-induced tumor cell lysis of squamous cell carcinomas of the upper aerodigestive tract. Head Neck 27: 376–382
Schmitt M, Schmitt A, Reinhardt P et al (2004) Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes. Int J Oncol 25:841–848
Hirschhaeuser F, Leidig T, Rodday B et al (2009) Test system for trifunctional antibodies in 3D MCTS culture. J Biomol Screen 14:980–990
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License ( https://creativecommons.org/licenses/by-nc/2.0 ), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
About this article
Cite this article
Schroeder, P., Lindemann, C., Dettmar, K. et al. Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment. Clin Transl Oncol 13, 889–898 (2011). https://doi.org/10.1007/s12094-011-0751-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-011-0751-5